lu mingxing graduated from city university of hong kong in 2020 with a ph.d. the scientific research direction is the development of new technologies for rna in situ and cellular immunotherapy. participated in key projects of the national natural science foundation of china to conduct research on combined immunotherapy strategies targeting breast cancer stem cells and mhc-ii+ neutrophils. received general funding from the china postdoctoral science foundation and hosted the project: methods and applications of crispr-dcas13-airid to capture rna-protein interactions in living cells.